Sharemaestro Newsreel

HeartFlow projects $246M-$250M 2026 revenue as Plaque outlook rises to $29M-$31M

Earnings Call Insights: HeartFlow (HTFL) Q2 2026 MANAGEMENT VIEW * "Q2 is an outstanding quarter for HeartFlow and the momentum that we entered 2026 with is accelerating," said (President, CEO & Director John Farquhar). "In the second quarter, revenue was $64.1 million, up 48% …

Doximity Doubled, Then Gave Most of It Back. Here’s Why the Market Doesn’t Trust the Rally

For a few hours on August 7, Doximity, Inc. (NYSE:DOCS) appeared to be the story of the earnings season. The medical-networking platform's stock more than doubled overnight following its fiscal first-quarter report, with CEO Jeffrey Tangney mentioning a metric that piqued traders' interest: the …

Waystar CEO Matthew Hawkins sells $2.06m in company stock

Waystar Holding Corp. CEO Matthew Hawkins sold approximately $2.06 million worth of company stock across two transactions in mid-August 2026, following the exercise of stock options. These sales were conducted under a Rule 10b5-1 trading plan. Despite the insider sales, Waystar reported strong Q2 …

Waystar (WAY) CEO Hawkins exercises 82,500 options and sells shares under plan

Waystar Holding Corp. CEO Matthew J. Hawkins exercised 82,500 stock options at $4.14 per share and subsequently sold the same number of shares in open-market transactions for approximately $25.0358 and $25.0121 per share. These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan. …

HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates

HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

Wellington Management reports 9.12% Heartflow (HTFL) stake in Schedule 13G/A

Wellington Management Group LLP and its related entities have filed an amended Schedule 13G (Amendment No. 3) for Heartflow, Inc. (HTFL), reporting a beneficial ownership of 9.12% of the common stock, totaling 7,864,226 shares as of June 30, 2026. The filing indicates shared voting …

Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

Heartflow, a leader in AI technology for diagnosing coronary artery disease, reported strong financial results for the second quarter of 2026, with total revenue increasing by 48% year-over-year to $64.1 million. The company also raised its full-year 2026 revenue guidance to between $246 million …

Heartflow posts Q2 2026 revenue $64.1M, raises 2026 revenue outlook to $246–250M

Heartflow reported strong second-quarter 2026 results with total revenue of $64.1 million, a 48% year-over-year increase, and significantly narrowed its non-GAAP net operating loss. The company achieved a record gross margin of 83.0% and raised its full-year 2026 revenue guidance to $246 million–$250 million. …

Heartflow soars 15% on earnings beat, raised guidance

Heartflow Inc. (NASDAQ:HTFL) reported strong second-quarter results, exceeding analyst expectations with an adjusted loss per share of -$0.07 and revenue of $64.1 million. The company also raised its full-year 2026 revenue guidance to $246 million-$250 million, leading to a 15% surge in after-hours trading. …

WAY (NASDAQ: WAY) insider plans sale of 51,360 shares after option exercises

An insider at Waystar Holding Corp. (NASDAQ: WAY) has filed a Form 144 indicating a planned sale of 51,360 common shares. This sale is scheduled for August 13, 2026, and follows option exercises for 7,882 and 43,478 shares on August 11, 2026, through Morgan …

Truist Lifts Doximity Target to $24 and Stays on Hold

This article first appeared on GuruFocus. Doximity (NYSE:DOCS), a digital platform for US medical professionals, rose 0.46% premarket after Truist Securities raised its price target to $24 from $19 and reiterated a Hold rating. The stock is already trading around that level. Truist now …

Privia Health’s (PRVA) Guidance Keeps Rising, So Is The Stock Keeping Pace?

Privia Health (NASDAQ:PRVA) just turned in a quarter that checked every box management set for itself, and then raised the bar again for the rest of the year. On the company's August 6 earnings call, CEO Parth Mehrotra and CFO David Mountcastle laid out …

HCAT Maintains by Wells Fargo -- Price Target Lowered to $1.50

Wells Fargo has maintained an Equal-Weight rating for Health Catalyst (HCAT) but lowered its price target to $1.50 from $1.75, citing concerns over growth expectations in a challenging healthcare environment. Despite this, GuruFocus assesses HCAT as 57.3% undervalued with a GF Value™ of $4.16 …

HeartFlow: Q2 Earnings Snapshot

HeartFlow Inc. (HTFL) reported a Q2 loss of $15.7 million, or 18 cents per share, which adjusted to 7 cents per share, beating analyst expectations. The medical technology company also surpassed revenue forecasts with $64.1 million for the period and projects full-year revenue between …

Heartflow earnings up next: Can Plaque Analysis sustain growth?

Heartflow Inc. is set to report second-quarter earnings, with analysts anticipating a loss of $0.19 per share, though year-over-year losses are narrowing significantly. Investors will be closely watching the adoption rates of its Plaque Analysis, the sustainability of its revenue growth, and its path …

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items. This …

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

Omnicell (OMCL) has raised its 2026 earnings outlook after a strong second quarter, though a significant portion of the profit improvement came from a one-time tariff refund. The company faces increased memory-chip costs expected to impact gross margins but plans to leverage cost control …

Privia Health (PRVA) Q2 2026 Earnings Call Transcript

Privia Health (PRVA) reported strong Q2 2026 results, with net income up 236.7% and total revenue increasing 21.4% year-over-year. The company expanded into New Jersey, now operating in 25 states, and highlighted the successful integration of recent acquisitions and the deployment of AI applications …

Truist cuts Waystar stock price target to $33 on valuation roll

Truist Securities has lowered its price target for Waystar Holding (NASDAQ:WAY) to $33 from $38, while maintaining a Buy rating. This adjustment follows Waystar's Q2 2026 results, with Truist updating its revenue and adjusted EBITDA projections upwards for 2026 and 2027. Despite the price …

Truist Adjusts Price Target on Waystar Holding to $33 From $38, Maintains Buy Rating

Truist has lowered its price target for Waystar Holding (WAY) to $33 from $38, while reaffirming its "Buy" rating on the stock. This adjustment comes amidst other analyst revisions, with Waystar Holding also reporting its Q2 2026 earnings, revenue increases, and revised 2026 outlook.

AI Chronic Care Platform Adds Fifth Fortune 50 Client, Lifts Margin to 62%

DarioHealth Corp. (DRIO:NASDAQ) reported strong Q2 2026 results, with revenue reaching $5.2 million and gross margin increasing to 62%. The AI-powered chronic care platform secured its fifth Fortune 50 client and expanded into provider-backed care, contributing to a contracted annual recurring revenue (ARR) of …

The 5 Most Interesting Analyst Questions From Doximity’s Q2 Earnings Call

The Top 5 Analyst Questions From Privia Health’s Q2 Earnings Call

Privia Health's Q2 results showed strong revenue growth but missed non-GAAP profit expectations, leading to a negative market reaction. Management attributed revenue growth to robust provider signings and expanded value-based attributed lives. This article highlights the top five analyst questions from the earnings call, …

Phreesia, Inc. $PHR Stake Lessened by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its stake in Phreesia, Inc. (NYSE:PHR) by 22.9% in the first quarter, selling 143,563 shares and retaining 484,717 shares valued at $4.07 million. Despite this reduction, institutional investors collectively own 92.1% of the company. Phreesia reported strong Q1 earnings …

Stifel Maintains Weave Communications(WEAV.US) With Buy Rating, Maintains Target Price $8

Stifel has reiterated its Buy rating on Weave Communications (WEAV.US) and maintained its target price of $8. This indicates the firm's continued confidence in the company's performance and future prospects at the current valuation.

Heartflow CEO John Farquhar sells $638,730 in common stock

Heartflow CEO John C.M. Farquhar sold 22,562 shares of the company's common stock for approximately $638,730. This transaction was executed under a Rule 10b5-1 trading plan. The company recently reported strong Q1 2026 earnings, exceeding analyst expectations, and has received positive ratings from several …

Waystar Holding Corp. (WAY) Stock forecasts

This article provides a stock forecast for Waystar Holding Corp. (WAY), identifying it as a provider of mission-critical cloud technology to healthcare organizations. It highlights a report from Argus dated August 12, 2026, which includes a current price of $25.08 and a price target …

Hinge Health (HNGE) director gains indirect ownership of 4,637 Class A shares

Hinge Health, Inc. director Teddie Benjamin Wardi indirectly acquired 4,637 shares of Class A Common Stock. These shares were received by Ingentorsk (Delaware) LLC through distributions from Insight Venture Associates X, L.P. and Insight Venture Partners X (Class A), L.P., with no monetary consideration …

Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 22,562 Shares

Heartflow CEO John C.M. Farquhar sold 22,562 shares of the company's stock for over $638,000, reducing his direct holdings by 4.92%. This transaction was made under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Heartflow's stock rose 1.0%, and the company exceeded …

Omada Health (NASDAQ:OMDA) President Sells 8,866 Shares

Omada Health's President, Wei-Li Shao, sold 8,866 shares of OMDA stock for $221,827, reducing his direct stake by 2.8%. This sale occurred after Omada Health reported a strong second quarter, with EPS of $0.08 and revenue of $87.83 million, exceeding analyst expectations. Despite positive …

Omada Health president Wei-Li Shao sells $221,798 in stock By Investing.com

Wei-Li Shao, President of Omada Health Inc. (NASDAQ:OMDA), sold 8,866 shares of the company's common stock for $221,798 on August 12, 2026, executed via a 10b5-1 trading plan. This sale occurred after the stock surged 114% over six months, with InvestingPro analysis suggesting it …

Veeva Systems (VEEV) Exceeds Market Returns: Some Facts to Consider

Veeva Systems (VEEV) closed at $241.51 in the latest trading session, marking a +2.08% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.26% for the day. On the other hand, the Dow registered a loss of …